Efficacy and safety of sucroferric oxyhydroxide on hemodialysis patients

Efficacy and safety of sucroferric oxyhydroxide on hemodialysis patients - Efficacy of sucroferric oxyhydroxide on HD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032867

Enrollment

Registered

2018-06-05

Start date

2016-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Sucroferric oxyhydroxide Lanthanum carbohydrate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) age > 19 years and < 86 years, (2) hemodialysis duration >6 months at enrollment, and (3) hyperphosphatemia that was treated with lanthanum carbonate at least 12 weeks before enrollment.

Exclusion criteria

Exclusion criteria: (1) age < 20 years or > 85 years; (2) history of severe heart failure, angina, myocardial infarction, or stroke within the past 6 months; (3) presence of infectious disease, malignant tumors, or treatment with steroids or immunosuppressants; (4) current hospitalization; and (5) treatment with ferric citrate hydrate within the past 6 months.

Design outcomes

Primary

Measure	Time frame
FGF23 levels and anemia-related parameters	—

Secondary

Measure	Time frame
Ca, P, intact-PTH levels safety	—

Countries

Japan

Contacts

Public ContactTomoyasu Otsuki

Nihon University School of Medicine Nephrology, Hypertension and Endocrinology

totsuki16@gmail.com03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026